{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:03:35Z","timestamp":1784779415082,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16286-7","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:45:07Z","timestamp":1780731907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An integrated pathway mutation and clinical model predicts survival in unresectable HCC with hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab"],"prefix":"10.1186","volume":"26","author":[{"given":"Shuangyan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"1","key":"16286_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"16286_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"16286_CR3","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.4254\/wjh.v7.i12.1632","volume":"7","author":"MH Attwa","year":"2015","unstructured":"Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(12):1632\u201351.","journal-title":"World J Hepatol"},{"key":"16286_CR4","doi-asserted-by":"publisher","first-page":"791013","DOI":"10.4061\/2011\/791013","volume":"2011","author":"L Barbier","year":"2011","unstructured":"Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol. 2011;2011:791013.","journal-title":"Int J Hepatol"},{"issue":"10126","key":"16286_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London England). 2018;391(10126):1163\u201373.","journal-title":"Lancet (London England)"},{"issue":"10088","key":"16286_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet (London England). 2017;389(10088):2492\u2013502.","journal-title":"Lancet (London England)"},{"issue":"7","key":"16286_CR7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"20","key":"16286_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"16suppl","key":"16286_CR9","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/JCO.2022.40.16_suppl.4106","volume":"40","author":"Y-K Gu","year":"2022","unstructured":"Gu Y-K, Zhang T-Q, Zuo M-X, Geng Z-J, Li J-B, Huang Z-L, Wu P-H. Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study). J Clin Oncol. 2022;40(16suppl):4106\u20134106.","journal-title":"J Clin Oncol"},{"key":"16286_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, Li Q, Xu L, Zhang Y, Wei W, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377.","journal-title":"Eur J Cancer"},{"key":"16286_CR11","doi-asserted-by":"publisher","first-page":"618206","DOI":"10.3389\/fonc.2021.618206","volume":"11","author":"J Mei","year":"2021","unstructured":"Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, Guo RP. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Front Oncol. 2021;11:618206.","journal-title":"Front Oncol"},{"issue":"1","key":"16286_CR12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","volume":"21","author":"S Chen","year":"2021","unstructured":"Chen S, Xu B, Wu Z, Wang P, Yu W, Liu Z, Huang X, Wu Y, Li T, Guo W. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer. 2021;21(1):1126.","journal-title":"BMC Cancer"},{"issue":"null","key":"16286_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2147\/JHC.S417550","volume":"10","author":"S Chen","year":"2023","unstructured":"Chen S, Shi F, Wu Z, Wang L, Cai H, Ma P, Zhou Y, Mai Q, Wang F, Tang S, et al. Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study. J hepatocellular carcinoma. 2023;10(null):1209\u201322.","journal-title":"J hepatocellular carcinoma"},{"issue":"7","key":"16286_CR14","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1097\/JS9.0000000000001378","volume":"110","author":"R Guan","year":"2024","unstructured":"Guan R, Zhang N, Deng M, Lin Y, Huang G, Fu Y, Zheng Z, Wei W, Zhong C, Zhao H, et al. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors. Int J Surg. 2024;110(7):4062\u201373.","journal-title":"Int J Surg"},{"issue":"1","key":"16286_CR15","doi-asserted-by":"publisher","first-page":"e000442","DOI":"10.1136\/esmoopen-2018-000442","volume":"4","author":"R Buttner","year":"2019","unstructured":"Buttner R, Longshore JW, Lopez-Rios F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1):e000442.","journal-title":"ESMO Open"},{"issue":"2","key":"16286_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"11","key":"16286_CR17","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/1878-0261.13203","volume":"16","author":"J Han","year":"2022","unstructured":"Han J, Yang Y, Li X, Wu J, Sheng Y, Qiu J, Wang Q, Li J, He Y, Cheng L, et al. Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. Mol Oncol. 2022;16(11):2153\u201373.","journal-title":"Mol Oncol"},{"issue":"8076","key":"16286_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41586-025-09203-8","volume":"644","author":"Y Dai","year":"2025","unstructured":"Dai Y, Knisely A, Yano M, Dang M, Hinchcliff EM, Lee S, Welp A, Chelvanambi M, Lastrapes M, Liu H, et al. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature. 2025;644(8076):537\u201346.","journal-title":"Nature"},{"issue":"15","key":"16286_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp1709968","volume":"377","author":"S Lemery","year":"2017","unstructured":"Lemery S, Keegan P, Pazdur R. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med. 2017;377(15):1409\u201312.","journal-title":"N Engl J Med"},{"issue":"17","key":"16286_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, et al. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1\/PD-L1 Blockade in Advanced Urothelial Cancers. J Clin Oncol. 2018;36(17):1685\u201394.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16286_CR21","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1038\/s41467-025-60457-2","volume":"16","author":"BM Lehrich","year":"2025","unstructured":"Lehrich BM, Delgado ER, Yasaka TM, Liu S, Cao C, Liu Y, Taheri MN, Guan X, Koeppen H, Singh S, et al. Precision targeting of \u03b2-catenin induces tumor reprogramming and immunity in hepatocellular cancers. Nat Commun. 2025;16(1):5009.","journal-title":"Nat Commun"},{"key":"16286_CR22","doi-asserted-by":"crossref","unstructured":"Li X, He Y, Wu J, Qiu J, Li J, Wang Q, Jiang Y, Han J. A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy. Brief Bioinform. 2022;23(5):bbac360.","DOI":"10.1093\/bib\/bbac360"},{"issue":"2","key":"16286_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/jcrt.jcrt_1078_21","volume":"18","author":"Z Wu","year":"2022","unstructured":"Wu Z, Gao J, Zhuang W, Yang J, Guo W. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk. J Cancer Res Ther. 2022;18(2):345\u201351.","journal-title":"J Cancer Res Ther"},{"key":"16286_CR24","doi-asserted-by":"crossref","unstructured":"Li J, Hu H, Qin G, Bai F, Wu X, Ke H, Zhang J, Xie Y, Wu Z, Fu Y et al. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer. Clin Cancer Res. 2024;30(2):368\u201378.","DOI":"10.1158\/1078-0432.CCR-23-2213"},{"issue":"4","key":"16286_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3642","volume":"14","author":"D Chaussabel","year":"2014","unstructured":"Chaussabel D, Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol. 2014;14(4):271\u201380.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"16286_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014;15(2):195\u2013204.","journal-title":"Nat Immunol"},{"issue":"5","key":"16286_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jtho.2017.01.005","volume":"12","author":"T Karasaki","year":"2017","unstructured":"Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, et al. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. J Thorac Oncol. 2017;12(5):791\u2013803.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"16286_CR28","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin cancer research: official J Am Association Cancer Res. 2019;25(7):2116\u201326.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"16286_CR29","doi-asserted-by":"publisher","first-page":"175883592110027","DOI":"10.1177\/17588359211002720","volume":"13","author":"MK He","year":"2021","unstructured":"He MK, Liang RB, Zhao Y, Xu YJ, Chen HW, Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17588359211002720.","journal-title":"Ther Adv Med Oncol"},{"issue":"17","key":"16286_CR30","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2217\/imt-2021-0192","volume":"13","author":"BJ Liu","year":"2021","unstructured":"Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021;13(17):1395\u2013405.","journal-title":"Immunotherapy"},{"key":"16286_CR31","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2147\/JHC.S418387","volume":"10","author":"X Chang","year":"2023","unstructured":"Chang X, Wu H, Ning S, Li X, Xie Y, Shao W, Yu J. Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study. J hepatocellular carcinoma. 2023;10:1497\u2013509.","journal-title":"J hepatocellular carcinoma"},{"key":"16286_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","volume":"85","author":"J Jiang","year":"2022","unstructured":"Jiang J. Hedgehog signaling mechanism and role in cancer. Sem Cancer Biol. 2022;85:107\u201322.","journal-title":"Sem Cancer Biol"},{"key":"16286_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-031-12974-2_3","volume":"1393","author":"G Hassan","year":"2022","unstructured":"Hassan G, Seno M. ERBB Signaling Pathway in Cancer Stem Cells. Adv Exp Med Biol. 2022;1393:65\u201381.","journal-title":"Adv Exp Med Biol"},{"key":"16286_CR34","doi-asserted-by":"crossref","unstructured":"Panera N, Crudele A, Romito I, Gnani D, Alisi A. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci. 2017;18(1):99.","DOI":"10.3390\/ijms18010099"},{"key":"16286_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","volume":"85","author":"J Jiang","year":"2022","unstructured":"Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107\u201322.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"16286_CR36","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/carcin\/bgi378","volume":"27","author":"S Huang","year":"2006","unstructured":"Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, Zhang K, Tang W, Stelter AA, Wang Q, et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis. 2006;27(7):1334\u201340.","journal-title":"Carcinogenesis"},{"issue":"2","key":"16286_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/hep.22649","volume":"49","author":"M Eichenmuller","year":"2009","unstructured":"Eichenmuller M, Gruner I, Hagl B, Haberle B, Muller-Hocker J, von Schweinitz D, Kappler R. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology. 2009;49(2):482\u201390.","journal-title":"Hepatology"},{"key":"16286_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2014.07.009","volume":"31","author":"I Eke","year":"2015","unstructured":"Eke I, Cordes N. Focal adhesion signaling and therapy resistance in cancer. Semin Cancer Biol. 2015;31:65\u201375.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"16286_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10585-010-9306-3","volume":"27","author":"JS Chen","year":"2010","unstructured":"Chen JS, Huang XH, Wang Q, Chen XL, Fu XH, Tan HX, Zhang LJ, Li W, Bi J. FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastas. 2010;27(2):71\u201382.","journal-title":"Clin Exp Metastas"},{"issue":"8","key":"16286_CR40","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, et al. beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov. 2019;9(8):1124\u201341.","journal-title":"Cancer Discov"},{"issue":"3","key":"16286_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","volume":"153","author":"D Sia","year":"2017","unstructured":"Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology. 2017;153(3):812\u201326.","journal-title":"Gastroenterology"},{"issue":"6","key":"16286_CR42","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/gutjnl-2023-331342","volume":"73","author":"N Cai","year":"2024","unstructured":"Cai N, Cheng K, Ma Y, Liu S, Tao R, Li Y, Li D, Guo B, Jia W, Liang H, et al. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy. Gut. 2024;73(6):985\u201399.","journal-title":"Gut"},{"issue":"6","key":"16286_CR43","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/hep.32458","volume":"76","author":"M Huang","year":"2022","unstructured":"Huang M, Jiao J, Cai H, Zhang Y, Xia Y, Lin J, Shang Z, Qian Y, Wang F, Wu H, et al. C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner. Hepatology. 2022;76(6):1706\u201322.","journal-title":"Hepatology"},{"issue":"10","key":"16286_CR44","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.4049\/jimmunol.0901747","volume":"183","author":"S Radfar","year":"2009","unstructured":"Radfar S, Wang Y, Khong HT. Activated CD4\u2009+\u2009T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol. 2009;183(10):6800\u20137.","journal-title":"J Immunol"},{"key":"16286_CR45","doi-asserted-by":"crossref","unstructured":"Zhang WW, Tong S, Hu BY, Wan T, Tang HW, Zhao FL, Jiao TY, Li JF, Zhang Z, Cai JP, et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J Immunother Cancer. 2023;11(9):e007366.","DOI":"10.1136\/jitc-2023-007366"},{"key":"16286_CR46","doi-asserted-by":"crossref","unstructured":"Guo XY, Nie H, Zhang WW, Li JS, Ge J, Xie BW, Hu WB, Zhu YC, Zhong N, Zhang XM, et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell. 2025;43(2):248\u201368.","DOI":"10.1016\/j.ccell.2025.01.001"},{"issue":"12","key":"16286_CR47","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41416-020-0817-7","volume":"122","author":"A Briggs","year":"2020","unstructured":"Briggs A, Daniele B, Dick K, Evans TRJ, Galle PR, Hubner RA, Lopez C, Siebert U, Tremblay G. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Br J Cancer. 2020;122(12):1754\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"16286_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","volume":"7","author":"M Pinter","year":"2021","unstructured":"Pinter M, Jain RK, Duda DG. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2021;7(1):113\u201323.","journal-title":"JAMA Oncol"},{"issue":"21","key":"16286_CR49","doi-asserted-by":"publisher","first-page":"10279","DOI":"10.1111\/jcmm.16966","volume":"25","author":"E Xu","year":"2021","unstructured":"Xu E, Su K, Zhou Y, Gong L, Xuan Y, Liao M, Cao J, Li Y, Lu Y, Zhao Y, et al. Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan-cancer cohort. J Cell Mol Med. 2021;25(21):10279\u201390.","journal-title":"J Cell Mol Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16286-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:22:01Z","timestamp":1784776921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16286-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16286"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16286-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (2019\u2009\u2212\u2009239). All patients provided written informed consent for the collection of tissue and blood samples for research and genomic profiling, as approved by the First Affiliated Hospital of Sun Yat-sen University.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have made a substantial contribution to this article and consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Longlong Gong, Lihua Zhao and Lijia Wu were employed by Genecast Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"887"}}